A flavonoid synthase mutant and its application in the fermentation production of apigenin

By performing site-directed mutagenesis and optimization on flavonoid synthase I, combined with an inorganic salt basal culture medium and an efficient purification method, the problems of enzyme stability and product separation and purification were solved, achieving efficient and low-cost production of apigenin.

CN123063357APending Publication Date: 2026-11-10CHINA NEW ERA HOLDINGS GROUP CO LTD +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202611309578.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-08-27
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

The existing technology for flavonoid synthase FNS I has insufficient enzyme stability, difficulty in fermentation scale-up, and difficulty in product separation and purification, resulting in low production efficiency, high cost, and instability of apigenin.

Method used

By site-directed mutagenesis of flavonoid synthase I to optimize its amino acid sequence, combined with the use of inorganic salt basal culture medium and whole-cell catalyst, and purified by methods such as membrane separation, acid-base precipitation and ion exchange resin, a highly efficient apigenin production process was developed.

Benefits of technology

It significantly improves the storage stability and catalytic activity of the enzyme, increases the yield and purity of apigenin, reduces production costs, and simplifies the process, making it suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123063357A_ABST
    Figure CN123063357A_ABST
Patent Text Reader

Abstract

This invention, entitled "A Flavonoid Synthase Mutant and Its Application in the Fermentation Production of Apigenin," belongs to the field of enzyme engineering technology. The technical problem to be solved is to provide an AcFNS-I mutant to address the shortcomings in existing technologies, such as insufficient catalytic activity of flavonoid synthases, difficulties in fermentation scale-up, and difficulties in separation and purification due to the structural similarity between apigenin and naringenin. The key technical solution is to provide an AcFNS-I mutant, the amino acid sequence of which is shown in any one of SEQ ID NO: 2-7. The mutant is selected from any one of F65A, F65A-G263M, F65A-Q85E, F65A-G263M-V167K, F65A-Q85E-G263I, or F65A-Q85E-N273S, and its catalytic activity is 2.47-6.58 times that of the wild type.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of enzyme engineering technology, specifically enzyme catalysis engineering and synthetic biology technology, and specifically relates to a flavonoid synthase mutant and its application in the fermentation production of apigenin. Background Technology

[0002] Apogenin (CAS: 520-36-5, 4',5,7-trihydroxyflavone) is a natural flavonoid compound with multiple biological activities, including anti-inflammatory, antioxidant, neuroprotective, and antitumor effects. Current traditional production methods face bottlenecks: chemical synthesis methods have low yields, heavy pollution, and high costs; plant extraction methods have low content, high costs, and inconsistent quality between batches.

[0003] Enzymatic synthesis, with flavonoid synthase I (FNS I) catalyzing the dehydrogenation of naringenin at the C2-C3 position to produce apigenin as the core reaction, has become an ideal alternative due to its green and efficient nature.

[0004] Relevant patent documents retrieved: The publication country is China, publication number CN110616204A, publication date 2019.12.27, entitled "Flavone Synthase and Its Applications". This document discloses a flavonoid synthase and its applications. The flavonoid synthase is selected from: (a) a polypeptide with a specific amino acid sequence; or (b) a polypeptide derived from (a) with flavonoid synthase activity formed by substitution, deletion, or addition of one or more amino acid residues of the above-mentioned specific amino acid sequence; or (c) a polypeptide derived from (a) with at least 85% sequence identity with the above-mentioned specific amino acid sequence and flavonoid synthase activity. This flavonoid synthase can realize the conversion and preparation of various flavonoid compounds, including apigenin, and has better catalytic efficiency, with a conversion efficiency superior to existing types of FNS I, and can be used for the construction and optimization of flavonoid compound cell factories.

[0005] Relevant non-patent literature retrieved: The document, titled "Study on Metabolic Engineering of Yersinia lipolytica for Apigenin Synthesis," by Wang Yuhui, Hunan Agricultural University, and published on May 1, 2024, discloses a method for green synthesis of apigenin using Yersinia lipolytica as the chassis cell through metabolic engineering and fermentation optimization strategies. Using Yersinia lipolytica Po1f(Δku70) as the chassis cell, engineered strains were constructed by overexpressing FNS-encoding genes for flavonoid synthases from different sources. Furthermore, the yield of apigenin was increased by extending the fermentation time and optimizing the conditions for adding exogenous precursors.

[0006] The prior art represented by the aforementioned documents has at least the following unresolved technical problems or defects: (1) Insufficient enzyme stability: Existing technologies lack a systematic evaluation of the storage stability of FNS enzymes from the perspective of industrial applications, while the storage stability of enzymes is a key factor in meeting the requirements of industrial enzyme solution preparation, storage, and feeding sequence. (2) Difficulty in fermentation scale-up: There are fundamental differences between laboratory shake flask conditions and industrial production tanks in terms of mixing and mass transfer, dissolved oxygen control, and feeding strategies. Maintaining the soluble expression and catalytic activity of enzymes while maintaining high-density culture is the core challenge of fermentation scale-up. (3) Difficulty in product separation and purification: The substrate naringenin and the product apigenin in the reaction system have highly similar structures (both are flavonoid tricyclic skeletons, differing only in C2-C3 bond order, with molecular weights of 272.25 and 270.24, respectively). Their polarity and chromatographic behavior are extremely similar. Existing purification methods (silica gel column chromatography, acid-base precipitation, organic solvent crystallization) are all general methods, lacking a dedicated separation strategy designed for the structural similarity between apigenin and naringenin. The purification of apigenin is significantly lower than the industry standard of greater than 98%. Summary of the Invention

[0007] The purpose of this invention is to provide: A flavonoid synthase mutant and its application in the fermentation production of apigenin, and related technologies, to solve technical problems such as insufficient enzyme stability, difficulty in fermentation scale-up, and difficulty in product separation and purification in existing technologies, or combinations thereof.

[0008] Terminology Explanation: Unless otherwise defined, all technical terms in this document have the same meanings as commonly understood by one of ordinary skill in the art to which the subject matter of the claims pertains. Unless otherwise stated, all patents, patent inventions, and publications cited in this document are incorporated herein by reference in their entirety. If multiple definitions exist for terms in this document, the definitions in this chapter shall prevail.

[0009] It should be understood that the above brief description and the following detailed description are exemplary and for illustrative purposes only, and do not limit the subject matter of the invention in any way. In this invention, the singular is used in conjunction with the plural unless otherwise specifically stated. It should also be noted that, unless otherwise stated, the use of “or” or “or” means “and / or”. Furthermore, the use of the term “comprising” and other forms such as “including,” “containing,” and “contains” are not limiting.

[0010] Definitions of the standard terminology can be found in the references “Molecular Cloning: A Laboratory Manual (Sambrook J, Russell D W. Molecular Cloning: A Laboratory Manual. 3rd ed. Cold Spring Harbor Laboratory Press, 2001),” “Microbiology Tutorial (4th Edition), Higher Education Press, author: Zhou Deqing, 2020,” “Modern Molecular Biology (5th Edition), Higher Education Press, authors: Zhu Yuxian, Li Yi, Zheng Xiaofeng, and Guo Hongwei, 2019-06-19,” and “Genetic Engineering, Higher Education Press, 2013-08-01.”

[0011] Unless otherwise stated, conventional methods within the scope of the art, such as gene cloning, PCR amplification, site-directed mutagenesis, seamless cloning, heat shock transformation, microbial culture, and high-performance liquid chromatography detection, shall be used.

[0012] Unless specifically defined herein, the use of all commercially available products herein employs standard techniques. For example, it may be carried out using the manufacturer's instructions for use with the kit, or in accordance with methods known in the art or the description of this invention. The techniques and methods described herein can generally be implemented according to conventional methods well known in the art, based on the descriptions in the various summary and more specific documents cited and discussed in this specification.

[0013] The terms “optional / arbitrary” or “optionally / arbitrarily” mean that the event or situation described below may or may not occur, including both the occurrence and non-occurrence of the event or situation.

[0014] The term "flavonoid synthase I (FNS I)" used in this article refers to: a soluble Fe... 2+ / α-ketoglutarate dioxygenase superfamily, enzymes that catalyze the dehydrogenation of flavanones (such as naringenin) at the C2-C3 position of the C ring to produce flavonoids (such as apigenin).

[0015] As used in this article, the term "mutant" refers to a protein variant obtained by replacing one or more amino acid residues in the amino acid sequence of a parental / wild-type protein through site-directed mutagenesis.

[0016] The term "whole-cell catalyst" as used in this article refers to a catalyst that uses intact microbial cells obtained directly from fermentation culture as a catalytic reaction tool, without the need for cell disruption and enzyme extraction.

[0017] The term "inorganic salt basal medium" as used in this article refers to a culture medium that uses glucose as a carbon source, ammonium sulfate as a nitrogen source, phosphate as a buffer and phosphorus source, and magnesium sulfate as an inorganic salt component, without any organic nitrogen source (such as yeast extract or peptone).

[0018] In a first aspect, the present invention provides: an AcFNS-I mutant, the amino acid sequence of which is shown in any one of SEQ ID NO: 2-7.

[0019] The mutant is any one of the following: (i) The amino acid sequence is shown in SEQ ID NO:2, and has an F65A mutation relative to wild-type AcFNS-I (SEQ ID NO:1), named AcFNS-I-F65A; (ii) The amino acid sequence is shown in SEQ ID NO:3. Compared with wild-type AcFNS-I, it has F65A and G263M mutations and is named AcFNS-I-F65A-G263M. (iii) The amino acid sequence is shown in SEQ ID NO:4. Compared with wild-type AcFNS-I, it has F65A and Q85E mutations and is named AcFNS-I-F65A-Q85E; (iv) The amino acid sequence is shown in SEQ ID NO:5. Compared with wild-type AcFNS-I, it has F65A, G263M and V167K mutations and is named AcFNS-I-F65A-G263M-V167K. (v) The amino acid sequence is shown in SEQ ID NO:6. Compared with wild-type AcFNS-I, it has F65A, Q85E and G263I mutations and is named AcFNS-I-F65A-Q85E-G263I. (vi) The amino acid sequence is shown in SEQ ID NO:7. Compared with the wild type AcFNS-I, it has F65A, Q85E and N273S mutations and is named AcFNS-I-F65A-Q85E-N273S.

[0020] The wild-type AcFNS-I is derived from *Aethusa cynapium* (UniProt: A6XFT2), and its amino acid sequence is shown in SEQ ID NO:1. This enzyme retains approximately 50% of its activity after being stored at 4°C for 5 days, demonstrating good storage stability.

[0021] In a second aspect, the present invention provides: a nucleotide molecule that encodes the AcFNS-I mutant described in the first aspect.

[0022] According to some embodiments of the present invention, the nucleotide molecule is a nucleic acid sequence optimized by E. coli codon preference, as shown in SEQ ID NO:8-14.

[0023] The nucleotide molecule is any one of the following: (1) The nucleotide sequence is shown in SEQ ID NO:8, encoding wild-type AcFNS-I (SEQ ID NO:1); (2) The nucleotide sequence is shown in SEQ ID NO:9, encoding the AcFNS-I mutant AcFNS-I-F65A (SEQ ID NO:2); (3) The nucleotide sequence is shown in SEQ ID NO:10, encoding the AcFNS-I mutant AcFNS-I-F65A-G263M (SEQ ID NO:3); (4) The nucleotide sequence is shown in SEQ ID NO:11, encoding the AcFNS-I mutant AcFNS-I-F65A-Q85E (SEQ ID NO:4). (5) The nucleotide sequence is shown in SEQ ID NO:12, encoding the AcFNS-I mutant AcFNS-I-F65A-G263M-V167K (SEQ ID NO:5). (6) The nucleotide sequence is shown in SEQ ID NO:13, encoding the AcFNS-I mutant AcFNS-I-F65A-Q85E-G263I (SEQ ID NO:6). (7) The nucleotide sequence is shown in SEQ ID NO:14, which encodes the AcFNS-I mutant AcFNS-I-F65A-Q85E-N273S (SEQ ID NO:7).

[0024] Thirdly, the present invention provides a recombinant expression vector comprising the nucleotide molecules described in the second aspect.

[0025] The preferred backbone vector for the recombinant expression vector is pET-28a. It is understood that the backbone vector includes, but is not limited to, the aforementioned vector backbone.

[0026] The recombinant expression vector further includes at least one of a tag, an resistance selection gene, and a promoter operatively linked to the nucleotide molecule.

[0027] Fourthly, the present invention provides: a recombinant host cell, said recombinant host cell comprising the nucleotide molecule described in the second aspect or the recombinant expression vector described in the third aspect.

[0028] According to some embodiments of the present invention, the recombinant host cell may be Escherichia coli.

[0029] Furthermore, the recombinant host cell is preferably BL21(DE3).

[0030] Fifthly, the present invention provides: a method for producing apigenin, the method comprising: S101, the recombinant host cells expressing the AcFNS-I mutant of claim 1 are fermented in an inorganic salt basal medium to obtain bacterial cells; S102, in an aqueous reaction system, the bacterial cells are used as a whole-cell catalyst to catalyze the conversion of naringenin to apigenin, resulting in a reaction solution containing apigenin.

[0031] According to some embodiments of the present invention, the inorganic salt basal culture medium contains glucose, ammonium sulfate, phosphate and magnesium sulfate, and does not contain organic nitrogen sources (such as yeast extract, peptone, etc.).

[0032] Furthermore, the pH of the inorganic salt basal culture medium is 6.8-7.2, preferably 7.0.

[0033] Further, the inorganic salt basal culture medium comprises 15 g / L-25 g / L glucose, 3 g / L-7 g / L ammonium sulfate, 10 g / L-20 g / L phosphate, and 0.3 g / L-0.7 g / L magnesium sulfate, and contains no organic nitrogen source. Preferably, the inorganic salt basal culture medium comprises 20 g / L glucose, 5 g / L ammonium sulfate, 15 g / L phosphate, and 0.5 g / L magnesium sulfate, and contains no organic nitrogen source.

[0034] According to some embodiments of the present invention, the fermentation culture includes: culturing at 35℃-37℃ until OD 600 After reaching the predetermined value, the temperature was lowered to 18-28℃, and IPTG was added to a final concentration of 0.3mM-0.7mM for induction of expression. The induction time was 12-20 hours. Specifically, OD... 600 The expected value is 20-30.

[0035] For example, the fermentation culture includes: culturing at 37°C to OD. 600 After reaching the predetermined value, the temperature was lowered to 18-28℃, and IPTG was added to a final concentration of 0.5mM for induction of expression. The induction time was 16 hours.

[0036] The aqueous reaction system contains NaHCO3 buffer, substrate naringenin, 2-ketoglutarate, L-ascorbic acid sodium, FeSO4 and DMSO.

[0037] According to some embodiments of the present invention, in the aqueous reaction system, the concentration of the substrate naringenin is 5 g / L-10 g / L, the volume fraction of DMSO is 8%-12%, the molar equivalent of 2-ketoglutarate is 3-5 times that of the substrate naringenin, the molar equivalent of L-ascorbic acid sodium is 1-2 times that of the substrate naringenin, the concentration of FeSO4 is 100-500 μM, the concentration of NaHCO3 is 25-100 mM, and the amount of bacterial cells is 50 g / L-150 g / L. Preferably, in the aqueous reaction system, the concentration of the substrate naringenin is 7 g / L, the volume fraction of DMSO is 10%, the molar equivalent of 2-ketoglutarate is 4 times that of the substrate naringenin, the molar equivalent of L-ascorbic acid sodium is 2 times that of the substrate naringenin, the concentration of FeSO4 is 250 μM, the concentration of NaHCO3 is 50 mM, and the amount of bacterial cells is 100 g / L.

[0038] According to some embodiments of the present invention, the catalytic temperature is 20°C-30°C, and the catalytic time is 6h-24h. Exemplarily, the catalytic temperature can be 20°C, 21°C, 22°C, 23°C, 24°C, 25°C, 26°C, 27°C, 28°C, 29°C, 30°C, or any value within the range of any two of the above values, preferably 25°C. Exemplarily, the catalytic time can be 6h, 7h, 8h, 9h, 10h, 11h, 12h, 13h, 14h, 15h, 16h, 17h, 18h, 19h, 20h, 21h, 22h, 23h, 24h, or any value within the range of any two of the above values, preferably 6h.

[0039] Sixthly, the present invention provides a method for separating and purifying apigenin obtained in the production method described in the fifth aspect, comprising the following steps: S201, add 0.2%-0.3% diatomaceous earth by mass of the reaction mixture, and then remove large insoluble particles from the reaction solution in the production method using a microfiltration membrane or ultrafiltration membrane to obtain a clear solution; S202, adjust the pH of the clarified liquid to 2.5-5.0 to precipitate apigenin and naringenin, separate the solid and liquid, and collect the first precipitate; S203, the first precipitate is suspended in water and the pH is adjusted to 9.0-11.5, solid-liquid separation is performed to remove insoluble matter, and the first liquid phase is collected; S204, the first liquid phase is contacted with an ion exchange resin to remove ionic impurities and pigments, and a second liquid phase is obtained; S205, adjust the pH of the second liquid phase to 2.5-5.0 to cause apigenin to precipitate again, separate the solid and liquid phases, and collect the second precipitate; S206, the second precipitate is dissolved by heating with an organic solvent, and then cooled to crystallize, to obtain the purified crude apigenin.

[0040] According to some embodiments of the present invention, the large insoluble particles comprise the bacterial cells.

[0041] According to some embodiments of the present invention, in step S204, the volume ratio of the ion exchange resin to the first liquid phase is 1:5 to 1:20, and the contact time is 10-60 minutes. Preferably, the volume ratio is 1:10, and the contact time is 30 minutes.

[0042] According to some embodiments of the present invention, the solid-liquid separation method in steps S202 and S205 is centrifugation.

[0043] According to some embodiments of the present invention, in step S206, the organic solvent is selected from at least one of DMSO, ethanol, methanol and acetone.

[0044] According to some embodiments of the present invention, the heating and dissolving temperature is 40°C-80°C, and the cooling and crystallization temperature is 0-15°C. Preferably, the heating and dissolving temperature is 55°C, and the cooling and crystallization temperature is 4°C.

[0045] According to some embodiments of the present invention, when the separation and purification method is used for industrial scale-up, any one of the following conditions can be met: (1) Step S201 may use a ceramic membrane cross-flow filtration system; (2) For the solid-liquid separation in steps S202 and S205, plate and frame filter press or horizontal screw centrifuge shall be selected; (3) Step S204 can be replaced by resin columns in series or simulated moving bed continuous operation. According to some embodiments of the present invention, the separation and purification method may further include recrystallization and / or column chromatography for further purification.

[0046] Specifically, the method for separating and purifying apigenin further includes step S207, which involves preparing the crude apigenin product with 95% ethanol at a concentration of 15 g / L, heating it to 55℃-65℃ until it is completely dissolved, allowing it to cool naturally while stirring, cooling it to room temperature, then cooling it in an ice bath to ≤4℃, filtering it, collecting the filter cake, and drying it to obtain apigenin.

[0047] In a seventh aspect, the present invention provides apigenin prepared by the production method described in the fifth aspect or the separation and purification method described in the sixth aspect.

[0048] Eighthly, the present invention provides the application of the AcFNS-I mutant described in the first aspect in the preparation of apigenin.

[0049] Examples 1-3 of this invention at least support the protection scope of the "AcFNS-I mutant".

[0050] The term "AcFNS-I mutant" is derived from the foregoing explanation and / or the corresponding AcFNS-I-F65A, AcFNS-I-F65A-G263M, AcFNS-I-F65A-Q85E, AcFNS-I-F65A-G263M-V167K, AcFNS-I-F65A-Q85E-G263I, and AcFNS-I-F65A-Q85E-N273S in Examples 1-3. Therefore, those skilled in the art, through reasonable presumption, can conclude that the "AcFNS-I mutant," its subordinate concepts, its substantially equivalent technical means, and technical means that can replace it within the scope of conventional and common knowledge based on the existing level of technology, should all fall within the protection scope of the "AcFNS-I mutant."

[0051] The present invention has at least the following beneficial effects: Compared with the prior art, the present invention provides a flavonoid synthase mutant and its application in the fermentation production of apigenin, which has better technical effects, specifically reflected in the following aspects: 1. Compared with the prior art, the present invention has better technical effects in terms of enzyme catalytic activity.

[0052] Experimental tests showed that the wild-type AcFNS-I retained approximately 50% of its activity after 5 days of storage at 4°C, demonstrating superior storage stability compared to most FNS homologs reported in the prior art. Through three rounds of computationally driven iterative evolution, the activity of the AcFNS-I mutant of this invention was gradually increased to 6.58 times that of the wild-type.

[0053] 2. Compared with the existing technology, the present invention has better technical effect in terms of apigenin production.

[0054] According to experimental tests, the optimal mutant AcFNS-I-F65A-G263M-V167K achieved a apigenin yield of 3.5 g / L in a 1 L whole-cell catalytic system (naringenin conversion rate of approximately 50%). In existing technology CN110616204A, the naringenin conversion rates of DcFNS and AgFNS were 30.6% and 21.89%, respectively; and in the existing technology "Flavone Synthases and Their Applications," the apigenin yield of engineered Yersinia lipolytica in shake flasks was only 68.9 mg / L.

[0055] 3. Compared with the prior art, the present invention has better technical effect in terms of product purity.

[0056] The separation and purification method provided by this invention involves membrane separation, acid precipitation, alkali dissolution for impurity removal, ion exchange resin treatment, acid precipitation enrichment, and recrystallization. The purity of the crude product is 80%-90% (calculated using the HPLC area normalization method). After further recrystallization or column chromatography purification, the purity can reach over 98%.

[0057] 4. Compared with the prior art, the present invention has better technical effects in terms of reducing costs and simplifying the process.

[0058] The apigenin production method of this invention uses an inorganic salt-based culture medium, free of any organic nitrogen sources (such as yeast extract or peptone), resulting in low cost, well-defined composition, good batch-to-batch consistency, and no animal-derived components. The entire process is an aqueous reaction, without the use of specially treated organic solvents, and has a low wastewater treatment load. Furthermore, this production process meets the requirements for high-density fermentation, yields high output, and can be directly transferred to larger-scale industrial production. In addition, the apigenin production method uses whole-cell catalysis, eliminating the need for cell wall disruption and enzyme separation, making operation simple.

[0059] 5. Compared with the prior art, the present invention provides a technical solution with a different technical concept. The difference between the technical concept of the present invention and the prior art (such as CN110616204A) is that the prior art only involves the cloning and expression of wild-type flavonoid synthase, while the present invention, for the first time, significantly improves the catalytic activity of the enzyme by rationally designing and site-directed mutagenesis of key amino acid residues in the substrate binding pocket of AcFNS-I; at the same time, it is the first to combine high-density fermentation of inorganic salt basal medium with membrane separation-ion exchange purification process, realizing a complete technical solution from enzyme catalyst preparation to product purification. Attached Figure Description

[0060] Figure 1 This is a schematic diagram of the structural model of the active site of the AcFNS-I enzyme of the present invention, wherein, Figure 1 Figure A: Substrate 2-ketoglutarate and naringenin react with Fe in the enzyme catalytic pocket. 3+ The combination pattern; Figure 1 Figure B in the diagram: Participating Fe 2+ Conserved amino acid residues in coordination (His232 / His288 / Asp234 constitute Fe) 2+ (Coordination triangle, with Lys213 as the key proton acceptor).

[0061] Figure 2 This is a summary diagram of the three rounds of iterative mutation screening results of the AcFNS-I invention, in which... Figure 2 Figure A in the diagram shows the first round of single-point mutation (Rosetta ΔΔG + CataPro), with WT as the reference; where, Figure 2Figure B in the diagram shows the second round of two-site combined mutations (ESM2 + ML + CataPro), starting with the F65A backbone; among them, Figure 2 Figure C in the diagram shows the third round of three-point combination mutations, with F65A-G263M and F65A-Q85E as the backbones (orange / F65A-G263M backbone, red / F65A-Q85E backbone). All values ​​have been normalized to AcFNS-I WT (WT=1.00).

[0062] Figure 3 This is a graph showing the change in apigenin concentration over time in a 1L whole-cell catalytic reaction system of the AcFNS-I-F65A-G263M-V167K of the present invention.

[0063] Figure 4 This is a schematic flowchart of the method for isolating and purifying apigenin according to the present invention.

[0064] Figure 5 This is an HPLC comparison diagram of the purified apigenin product and the standard of the present invention.

[0065] Figure 6 The figure shows the results of whole-cell storage stability of AcFNS-I-F65A-G263M-V167K. Detailed Implementation

[0066] Unless otherwise specified, all raw materials and reagents used in this invention were purchased from commercial suppliers, and experiments were conducted in accordance with the operating instructions. Unless otherwise specified, all instruments, equipment, and apparatus used in this invention are conventional instruments, equipment, and apparatus, and experiments were conducted in accordance with the operating instructions and the accompanying reagents.

[0067] To make the objectives, technical solutions, and advantages of this invention clearer, the invention will be further described in detail below with reference to embodiments. Unless otherwise specified in the embodiments, conditions are performed under conventional conditions or conditions recommended by the manufacturer. All reagents or instruments without specified manufacturers are commercially available conventional products. Numerous specific details are provided in the following detailed embodiments to better illustrate the invention. The specific embodiments described herein are for illustrative purposes only and are not intended to constitute any limitation on the invention.

[0068] All data processing in this invention was performed using OriginPro 2024 software. Analysis between different groups was conducted using independent samples t-tests or one-way ANOVA tests. P <0.05 indicates that the difference is statistically significant.

[0069] Example 1: Preparation of AcFNS-I wild-type and mutant (1) Starter enzyme selection strategy: AcFNS-I was obtained from the enzyme database through AlphaFold3 structure modeling, Foldseek structure search, CataPro activity prediction and experimental verification. In the early screening (substrate naringenin about 3 g / L, no solubilizer), the yield of apigenin in 100 mL system was about 1 g / L; under the subsequent optimized catalytic conditions (substrate 7 g / L, 10% DMSO for solubilization), the wild-type yield reached about 1.5 g / L. In addition, the enzyme showed good expression and solubility in inorganic salt basal medium. Based on the above results, AcFNS-I was used as the starter enzyme for subsequent mutation modification and process development. The gene encoding the flavonoid synthase AcFNS-I from Aethusa cynapium (UniProt: A6XFT2) was obtained by querying the NCBI database (amino acid sequence is SEQ ID NO:1).

[0070] (2) Phased rational design and iterative evolution of AcFNS-I: Starting with the wild-type AcFNS-I, three rounds of iterative mutations were performed. The first round involved single-point mutations on the wild-type to obtain sites that enhanced activity. The optimal mutant from this round was then used as the backbone for a second round of two-site combinations. The optimal result from the second round was then used as the backbone for a third round of three-site combinations. Experimental data from each round were fed back into the mutation site prediction model for the next round.

[0071] (A) First round of mutations—initial screening of single-point mutations based on structural prediction First, the three-dimensional structure of AcFNS-I was predicted using AlphaFold3 (homological template 2BRT), and then a virtual mutation scan was performed on all sites. Specifically, the Rosetta energy function was used to calculate the ΔΔG of each site after replacing it with one of the other 19 amino acids to assess the impact on protein thermostability. For candidate mutations that passed the stability filter, the CataPro deep learning model was used to predict enzyme activity. Finally, the Rosetta ΔΔG and CataPro scores were combined for ranking, and the top-ranked sites were selected for experimental validation.

[0072] Please see Figure 2 Following this strategy, the first round of single-point mutant libraries (Lib1.0) were constructed and analyzed using 96-well OD plates. 380 High-throughput initial screening was performed, and positive clones were further screened by shake-flask HPLC. In the experimental data, F65A (relative to WT activity 2.47) was the positive mutation with the largest increase and was selected as the backbone for subsequent combined mutations. F65, located at the substrate-binding cavity entrance—the large aromatic side chain of phenylalanine—posed a steric barrier to the entry of the substrate naringenin. Replacing it with alanine removed the benzene ring, increasing the channel size.

[0073] (B) Second-round mutation—2-site mutation prediction based on ESM2 embedding and machine learning model The second round involved performing two-site combination mutations on the F65A backbone. Unlike the first round, this round did not rely solely on structural calculations; instead, it used the experimental data from the first round to train a machine learning model and then predicted candidate two-site mutations.

[0074] The specific process is as follows: (1) Extract the embedding vector of each candidate mutation sequence using the ESM2 protein language model (Meta AI, 650M parameter version, pre-trained with approximately 250 million sequences); (2) Use the mutant activity data from the first round of actual testing as the training set, and perform regression fitting using three models: Random Forest, XGBoost, and SVR. The input is the ESM2 embedding vector, and the output is the activity prediction value. The prediction performance of each model is evaluated using leave-one-out cross-validation; (3) For the candidate two-site mutations to be predicted, first use the average prediction score of the three ML models for initial screening, select the top 200 mutants, and then use CataPro for secondary scoring. The mutants entering the experiment are determined according to the final ranking.

[0075] Results of the second round of experiments: Among the positive mutants, F65A-G263M (score 5.06), F65A-G263I (4.25), F65A-N327R (4.20), F65A-G263L (4.08), F65A-Q85E (3.66), and F65A-G263F (3.36) showed positive substitutions at the G263 site in the second round (Met / Ile / Leu / Phe), indicating that this site has a crucial impact on catalytic efficiency. Structurally, G263 is located at the Fe-supporting site. 2+ The α-helix mid-segment of the coordinating residues His232 / His288; glycine lacks a side chain at this position, resulting in greater local flexibility of the helix. Replacing it with an amino acid with a large side chain enhances the helix rigidity, indirectly stabilizing Fe. 2+ Spatial arrangement of coordinating residues. Q85E (3.66) is located in the protein surface loop region and may affect the kinetic properties of the substrate channel by altering the local charge distribution.

[0076] In terms of prediction efficiency, the positive rate of the second round of screening using ML+CataPro was significantly higher than that of the first round which relied solely on structure calculation scoring, indicating that the ML model trained with the experimental data from the first round was effective.

[0077] (C) Third round of mutation—3-site iterative combinatorial optimization In the third round, the two best two-site mutants from the second round—F65A-G263M and F65A-Q85E—were used as the backbones, and the same ESM2→ML→CataPro process as the second round was used to perform three-site combination prediction.

[0078] Using F65A-G263M as the backbone, F65A-G263M-V167K (6.58) and F65A-G263M-S284E (5.77) were screened. Using F65A-Q85E as the backbone, F65A-Q85E-G263I (6.12), F65A-Q85E-G263V (5.96), F65A-Q85E-N273S (5.83), F65A-Q85E-S87M (4.31), and F65A-Q85E-N16P (4.20) were screened, with Q293L being a negative mutation (3.33). Among them, G263I and G263V continue to point to the key point of G263 site—introducing different hydrophobic side chain substitutions at this site under different backbone backgrounds can obtain activity gains. N273S also exhibited a relatively stable synergistic effect.

[0079] Please see Figure 2 The results of three rounds of iterative mutation screening for AcFNS-I are summarized. Through three rounds of iterative screening, the activity of AcFNS-I was progressively optimized. The optimal mutant was F65A-G263M-V167K, with a relative activity of approximately 5.5 to 5.8 times that of the wild type, making it the final winner of this screening. In addition, the F65A-Q85E-G263I combination also showed extremely strong application potential (~4.8 times). The screening process clearly demonstrated the effectiveness of the directed evolution strategy of "single-site screening → advantageous combination → fine optimization," and multiple sites (such as F65A, G263M, G263I, and Q85E) were identified as key positive effect sites for enhancing activity.

[0080] (D) Active site saturation mutation (product inhibition mitigation attempt) In the enzymatic reaction, apigenin, the product, was observed to have a feedback inhibitory effect on FNS enzyme. To find mutation sites that could alleviate product inhibition, saturation mutations were performed on 10 sites (T115, R129, F131, K197, T219, P221, G222, F292, N294, Y320) within 5 Å of the AcFNS-I active site. These 10 sites are distributed near the substrate inlet, the periphery of the catalytic center, and the product release channel, and theoretically may be involved in substrate / product binding or release. The saturation mutant library was subjected to high-throughput screening under stringent conditions of an equimolar ratio (1:1) of substrate and product to simulate the high product concentration environment in the later stages of the reaction.

[0081] Experimental results showed that none of the tested mutants exhibited significantly better activity than the wild type at high product concentrations. This indicates that not all mutations improve performance; substitution of a single amino acid is insufficient to overcome product inhibition. This may be because the inhibitory effect involves synergy at multiple sites or is related to overall enzyme conformational changes. Therefore, mutant design requires a more holistic approach.

[0082] (3) Preparation of AcFNS-I wild-type and mutant: The AcFNS-I wild-type or mutant encoding gene (amino acid sequences SEQ ID NO: 1-7, nucleotide sequences SEQ ID NO: 8-14, respectively) was cloned into the NdeI / XhoI site of the pET-28a expression vector to obtain an N-terminal 6×His tag fusion protein expression plasmid (recombinant expression vector). The plasmid was transformed into *E. coli* BL21(DE3) competent cells (recombinant host cells), and single clones (positive transformants) were picked and inoculated into 50 mL LB liquid medium (containing 50 μg / mL kanamycin) and cultured at 37°C until OD600. 600 =0.8, add IPTG to a final concentration of 0.5 mM, cool to 18℃ and induce for 16 hours to obtain strains expressing AcFNS-I wild type and mutant respectively.

[0083] SEQ ID NO: 1: AcFNS-I-WT (355 aa) MAPTTITALSQEKSLNLDFVRDEDERPKVAYNQFSNEIPIISLAGMDDDSNGRRPEICRKIVEAFEDWGIFQVVDHGIDKGLISQMSRLSREFFALPAEEKLRYDTTGGKRGGFTISTHLQGDDVKDWREFVTYFSYPIEDRDYSRWPEKPEGWRSTTEVYSEKLMVLGAKLLEVLSE AMGLEKEALTKACVNMEQKVLINYYPTCPEPDLTLGVRRHTDPGTITILLQDMVGGLQATRDGGKTWITVQPVEGAFVVNLGDHGHYLSNGRFKNADHQAVVNSTSSRLSIATFQNPAQNAIVYPLKIREGEKAILDEAITYAEMYKKNMTKHIEVAALKKLAKEKRLQDEKAKLEM.

[0084] SEQ ID NO:2: AcFNS-I-F65A (355 aa, F65→A) MAPTTITALSQEKSLNLDFVRDEDERPKVAYNQFSNEIPIISLAGMDDDSNGRRPEICRKIVEAAEDWGIFQVVDHGIDKGLISQMSRLSREFFALPAEEKLRYDTTGGKRGGFTISTHLQGDDVKDWREFVTYFSYPIEDRDYSRWPEKPEGWRSTTEVYSEKLMVLGAKLLEVLSE AMGLEKEALTKACVNMEQKVLINYYPTCPEPDLTLGVRRHTDPGTITILLQDMVGGLQATRDGGKTWITVQPVEGAFVVNLGDHGHYLSNGRFKNADHQAVVNSTSSRLSIATFQNPAQNAIVYPLKIREGEKAILDEAITYAEMYKKNMTKHIEVAALKKLAKEKRLQDEKAKLEM。

[0085] SEQ ID NO:3:AcFNS-I-F65A-G263M(355 aa,F65A,G263→M) MAPTTITALSQEKSLNLDFVRDEDERPKVAYNQFSNEIPIISLAGMDDDSNGRRPEICRKIVEAAEDWGIFQVVDHGIDKGLISQMSRLSREFFALPAEEKLRYDTTGGKRGGFTISTHLQGDDVKDWREFVTYFSYPIEDRDYSRWPEKPEGWRSTTEVYSEKLMVLGAKLLEVLSE AMGLEKEALTKACVNMEQKVLINYYPTCPEPDLTLGVRRHTDPGTITILLQDMVGGLQATRDGGKTWITVQPVEGAFVVNLGDHMHYLSNGRFKNADHQAVVNSTSSRLSIATFQNPAQNAIVYPLKIREGEKAILDEAITYAEMYKKNMTKHIEVAALKKLAKEKRLQDEKAKLEM。

[0086] SEQ ID NO:4:AcFNS-I-F65A-Q85E(355 aa,F65A,Q85→E) MAPTTITALSQEKSLNLDFVRDEDERPKVAYNQFSNEIPIISLAGMDDDSNGRRPEICRKIVEAAEDWGIFQVVDHGIDKGLISEMSRLSREFFALPAEEKLRYDTTGGKRGGFTISTHLQGDDVKDWREFVTYFSYPIEDRDYSRWPEKPEGWRSTTEVYSEKLMVLGAKLLEVLSE AMGLEKEALTKACVNMEQKVLINYYPTCPEPDLTLGVRRHTDPGTITILLQDMVGGLQATRDGGKTWITVQPVEGAFVVNLGDHGHYLSNGRFKNADHQAVVNSTSSRLSIATFQNPAQNAIVYPLKIREGEKAILDEAITYAEMYKKNMTKHIEVAALKKLAKEKRLQDEKAKLEM。

[0087] SEQ ID NO:5:AcFNS-I-F65A-G263M-V167K(355 aa,F65A,G263M,V167→K) MAPTTITALSQEKSLNLDFVRDEDERPKVAYNQFSNEIPIISLAGMDDDSNGRRPEICRKIVEAAEDWGIFQVVDHGIDKGLISQMSRLSREFFALPAEEKLRYDTTGGKRGGFTISTHLQGDDVKDWREFVTYFSYPIEDRDYSRWPEKPEGWRSTTEVYSEKLMKLGAKLLEVLSE AMGLEKEALTKACVNMEQKVLINYYPTCPEPDLTLGVRRHTDPGTITILLQDMVGGLQATRDGGKTWITVQPVEGAFVVNLGDHMHYLSNGRFKNADHQAVVNSTSSRLSIATFQNPAQNAIVYPLKIREGEKAILDEAITYAEMYKKNMTKHIEVAALKKLAKEKRLQDEKAKLEM。

[0088] SEQ ID NO:6:AcFNS-I-F65A-Q85E-G263I(355 aa,F65A,Q85E,G263→I) MAPTTITALSQEKSLNLDFVRDEDERPKVAYNQFSNEIPIISLAGMDDDSNGRRPEICRKIVEAAEDWGIFQVVDHGIDKGLISEMSRLSREFFALPAEEKLRYDTTGGKRGGFTISTHLQGDDVKDWREFVTYFSYPIEDRDYSRWPEKPEGWRSTTEVYSEKLMVLGAKLLEVLSE AMGLEKEALTKACVNMEQKVLINYYPTCPEPDLTLGVRRHTDPGTITILLQDMVGGLQATRDGGKTWITVQPVEGAFVVNLDGDHIHYLSNGRFKNADHQAVVNSTSSRLSIATFQNPAQNAIVYPLKIREGEKAILDEAITYAEMYKKNMTKHIEVAALKKLAKEKRLQDEKAKLEM。

[0089] SEQ ID NO:7:AcFNS-I-F65A-Q85E-N273S(355 aa,F65A,Q85E,N273→S) MAPTTITALSQEKSLNLDFVRDEDERPKVAYNQFSNEIPIISLAGMDDDSNGRRPEICRKIVEAAEDWGIFQVVDHGIDKGLISEMSRLSREFFALPAEEKLRYDTTGGKRGGFTISTHLQGDDVKDWREFVTYFSYPIEDRDYSRWPEKPEGWRSTTEVYSEKLMVLGAKLLEVLSE AMGLEKEALTKACVNMEQKVLINYYPTCPEPDLTLGVRRHTDPGTITILLQDMVGGLQATRDGGKTWITVQPVEGAFVVNLGDHGHYLSNGRFKSADHQAVVNSTSSRLSIATFQNPAQNAIVYPLKIREGEKAILDEAITYAEMYKKNMTKHIEVAALKKLAKEKRLQDEKAKLEM。

[0090] SEQ ID NO:8:AcFNS-I-WT SEQ ID NO:9:AcFNS-I-F65A SEQ ID NO:10:AcFNS-I-F65A-G263M SEQ ID NO:11:AcFNS-I-F65A-Q85E SEQ ID NO:12:AcFNS-I-F65A-G263M-V167K SEQ ID NO:13:AcFNS-I-F65A-Q85E-G263I SEQ ID NO:14:AcFNS-I-F65A-Q85E-N273S Example 2: Method for producing apigenin Step S101, Fermentation expression of AcFNS-I wild-type and mutant: The AcFNS-I wild-type and mutant strains obtained in Example 1 were inoculated at a 1% inoculum into an inorganic salt basal medium (20 g / L glucose, 5 g / L ammonium sulfate, 3 g / L KH2PO4, 15 g / L Na2HPO4·12H2O, 0.5 g / L MgSO4·7H2O, pH 7.0) and cultured at 37°C until OD200. 600 =0.8, add IPTG to a final concentration of 0.5 mM, cool to 18℃ and induce for 16 hours. Centrifuge at 4℃ (6000×g, 15 min) to collect the cells, weigh them and store at -20℃ as AcFNS-I whole-cell catalyst for later use.

[0091] Step S102, Whole-cell catalytic reaction of the AcFNS-I mutant: In an aqueous reaction system, the collected wet bacterial cells were directly used as whole-cell catalysts (without cell disruption or enzyme extraction) to catalyze the conversion of naringenin to apigenin, yielding a reaction solution containing apigenin. The aqueous reaction system (100 mL) consisted of: 50 mM NaHCO3 buffer (pH 8.0), 7 g / L naringenin substrate (dissolved with 10% DMSO), 4 molar equivalents of 2-ketoglutarate, 2 molar equivalents of L-ascorbic acid sodium, 250 μM FeSO4, 10% DMSO (v / v), and 50 g / L wet bacterial cells. The reaction was carried out at 30 °C with shaking at 200 rpm for 16 hours. The amount of apigenin produced was monitored by HPLC.

[0092] HPLC conditions: C18 reversed-phase column (250×4.6mm, 5μm), detection wavelength 290nm, mobile phase gradient elution of methanol-0.1% formic acid aqueous solution (0min: 20% methanol → 20min: 60% methanol → 25min: 20% methanol), flow rate 1.0mL / min, column temperature 30℃, injection volume 10μL. A standard curve was established using apigenin standard (purity ≥98%) for external standard quantification.

[0093] The results of apigenin production over 2 hours are shown in Table 1.

[0094] Table 1

[0095] The results showed that the wild-type AcFNS-I produced approximately 1.5 g / L of apigenin in a 100 mL system; the AcFNS-I-F65A mutant produced approximately 2.55 g / L of apigenin; and the optimal mutant AcFNS-I-F65A-G263M-V167K produced 3.5 g / L of apigenin in a 1 L system.

[0096] Example 3 High-density fermentation experiment The fermentation scale-up experiment was conducted using step S101 of the apigenin production method in Example 2 (fermentation expression of wild-type and mutant AcFNS-I: wild-type and mutant strains of AcFNS-I obtained in Example 1 were inoculated at a 1% inoculum into an inorganic salt basal medium (20 g / L glucose, 5 g / L ammonium sulfate, 3 g / L KH2PO4, 15 g / L Na2HPO4·12H2O, 0.5 g / L MgSO4·7H2O, pH 7.0), and cultured at 37℃ for 12 h to obtain a primary seed culture.

[0097] Prepare 40L of sterile culture medium in a 50L stainless steel fermenter according to the above inorganic salt basal culture medium formula. Inoculate with 2L of primary seed culture (LB) and incubate to OD. 600 Approximately 0.8). Incubate at 37℃ until OD... 600 The temperature was approximately 30°C. The temperature was then lowered to 28°C, and IPTG was added to a concentration of 0.5 mM to induce fermentation until completion (total fermentation time approximately 20 hours). Aeration was controlled at 1 vvm, and the stirring speed was 400 rpm to maintain dissolved oxygen at 40%. During the mid-to-late stages, a feedstock of glucose (total 13.41 L) was added to maintain carbon source supply. The cells were collected by centrifugation to obtain the OD (oxidative density). 600 =101.4, wet bacterial culture 7600g. This indicates that the 50 L fermenter in the production method provided by this invention can achieve OD... 600 =101.4, 7600 g of wet bacterial cells, this process can be directly transferred to a larger scale. Moreover, the whole-cell catalysis method does not require cell wall disruption and enzyme solution separation, making the operation simple.

[0098] Example 4 Catalytic Reaction Condition Test The whole-cell catalytic performance of the AcFNS-I mutant was investigated using step S102 of Example 2 (in an aqueous reaction system, collected wet bacterial cells were directly used as whole-cell catalysts (without cell disruption or enzyme extraction) to catalyze the conversion of naringenin to apigenin, resulting in a reaction solution containing apigenin. The aqueous reaction system consisted of: 50 mM NaHCO3 buffer (pH 8.0), 7 g / L naringenin substrate (dissolved with 10% DMSO), 4 molar equivalents of 2-ketoglutarate, 2 molar equivalents of L-ascorbic acid sodium, 250 μM FeSO4, 10% DMSO (v / v), and 100 g / L wet bacterial cells. The reaction was carried out at 30°C and 200 rpm for 16 hours with shaking. The amount of apigenin produced was monitored by HPLC). The whole-cell catalytic performance of the AcFNS-I wild-type and mutant was investigated using aqueous reaction systems of 100 mL and 1 L, respectively.

[0099] The results showed that the wild-type AcFNS-I produced approximately 1.5 g / L of apigenin in a 100 mL system and approximately 1.3 g / L in a 1 L system. The AcFNS-I-F65A mutant produced approximately 2.55 g / L of apigenin in a 100 mL system and approximately 2.3 g / L in a 1 L system. The optimal mutant AcFNS-I-F65A-G263M-V167K (relative to WT activity 6.58), obtained through three rounds of iterative evolution, achieved a apigenin production of 3.5 g / L in a 1 L system.

[0100] Please see Figure 3 The apigenin concentration of AcFNS-I-F65A-G263M-V167K in a 1 L whole-cell catalytic reaction system was measured as a plateau at 3.5 g / L after approximately 6 hours of reaction (3 replicates of F1, F2, and F3).

[0101] Example 4: Isolation and purification of apigenin Please see Figure 4 Using the apigenin production method of Example 2, the reaction solution containing apigenin obtained from the AcFNS-I-F65A-G263M-V167K mutant was used as raw material, and purification was carried out according to the following steps: S201, Membrane separation: Add 0.25% of diatomaceous earth by mass of the initial reaction solution to the initial reaction solution, filter the reaction solution with a 0.45μm polyethersulfone microfiltration membrane at 0.2MPa, retain the bacterial cells, and collect the permeate as the clear liquid; S202, acidification precipitation: adjust the pH of the permeate to 4.0 with hydrochloric acid, stir for 30 min, let stand at 4℃ for 2 h, and collect the first precipitate by centrifugation; S203, alkaline dissolution to remove impurities: The first precipitate is suspended in water, the pH is adjusted to 10.0 with NaOH solution, stirred for 30 min, centrifuged to remove insoluble matter, and the supernatant (first liquid phase) is collected. S204, Ion exchange resin treatment - The supernatant is added to the pretreated anion exchange resin (D201 type) at a volume ratio of 1:10, stirred and contacted for 30 min, and then filtered to separate the resin to obtain the second liquid phase. S205: Acid precipitation enrichment: Adjust the pH of the second liquid phase to 4.0 with hydrochloric acid to cause apigenin to precipitate again. Separate the solid and liquid phases, collect the precipitate, wash it twice with water to obtain the second precipitate. S206, recrystallization: Dissolve the second precipitate by heating with DMSO at about 55°C, slowly cool to about 4°C and allow to stand for crystallization, filter and vacuum dry to obtain apigenin; S207, Secondary recrystallization: Prepare a solution of crude apigenin with 95% ethanol at a concentration of 15 g / L, heat to 60°C until completely dissolved, allow to cool naturally while stirring, cool to room temperature, then cool in an ice bath to ≤4°C, filter, collect the filter cake, and dry to obtain apigenin.

[0102] The crude apigenin obtained in step S206 was approximately 5.5 g, with a content of approximately 82% as determined by HPLC. Please refer to [link / reference]. Figure 5 The purple spectral line represents the apigenin standard with a purity of 98.789% obtained by Maclean; the blue and black spectral lines represent the apigenin products obtained after purification from two repeated experiments of the same mutant. The retention times of the three are consistent, and the external standard method for peak area quantification results show that the purity of the final product can reach over 98% after further purification of the crude apigenin obtained in step S206 in step S207.

[0103] Example 5 AcFNS-I Storage Stability Test The AcFNS-I whole-cell catalyst prepared in step S101 of Example 2 was stored at 4°C. Every 24 hours, samples were taken to measure the catalytic activity (100 mL system) of the whole-cell catalytic reaction of the AcFNS-I mutant under HPLC conditions, referring to step S102 of Example 2.

[0104] The results are as follows Figure 6 As shown, the results indicate that after 5 days of storage, the whole-cell catalyst of the AcFNS-I mutant retained approximately 50% of its original activity, demonstrating good storage stability and meeting the requirements for industrial enzyme preparation, storage, and feeding sequence.

[0105] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, and is not intended to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions made by those skilled in the art to the technical solution of the present invention do not depart from the essence and scope of the technical solution of the present invention.

Claims

1. An AcFNS-I mutant, characterized in that, The amino acid sequence of the AcFNS-I mutant is shown in any one of SEQ ID NO:2-7.

2. A nucleotide molecule, characterized in that, The nucleotide molecule encodes the AcFNS-I mutant of claim 1.

3. A recombinant expression vector, characterized in that, The recombinant expression vector comprises the nucleotide molecule of claim 2.

4. A recombinant host cell, characterized in that, The recombinant host cell comprises the nucleotide molecule of claim 2, or the recombinant expression vector of claim 3.

5. A method for producing apigenin, characterized in that, The production method includes: S101, the recombinant host cells expressing the AcFNS-I mutant of claim 1 are fermented in an inorganic salt basal medium to obtain bacterial cells; S102, in an aqueous reaction system, the bacterial cells are used as a whole-cell catalyst to catalyze the conversion of naringenin to apigenin, resulting in a reaction solution containing apigenin.

6. The production method according to claim 5, characterized in that, The inorganic salt basal culture medium contains glucose, ammonium sulfate, phosphate and magnesium sulfate, and does not contain organic nitrogen sources.

7. The production method according to claim 5, characterized in that, The fermentation culture includes: culturing at 35℃-37℃ until OD. 600 After reaching a concentration of 0.6-1.0, the temperature is lowered to 18-28℃, and IPTG is added to a final concentration of 0.3mM-0.7mM for induction of expression. The induction time is 12-20 hours.

8. The production method according to claim 5, characterized in that, The aqueous reaction system contains NaHCO3 buffer, naringenin as a substrate, 2-ketoglutarate, and DMSO.

9. The production method according to claim 8, characterized in that, In the aqueous reaction system, the concentration of the substrate naringenin is 5 g / L-10 g / L, the volume fraction of DMSO is 8%-12%, the molar equivalent of 2-ketoglutarate is 3-5 times that of the substrate naringenin, the molar equivalent of sodium L-ascorbate is 1-2 times that of the substrate naringenin, the concentration of FeSO4 is 100-500 μM, the concentration of NaHCO3 is 25-100 mM, and the amount of bacterial cells is 50 g / L-150 g / L.

10. The production method according to claim 5, characterized in that, The catalytic temperature is 20℃-30℃, and the catalytic time is 6h-24h.

11. A method for separating and purifying apigenin obtained in the production method of claim 5, characterized in that, Includes the following steps: S201, large insoluble particles in the reaction solution are removed by microfiltration or ultrafiltration membrane to obtain a clear solution; S202, adjust the pH of the clarified liquid to 2.5-5.0 to precipitate apigenin and naringin, separate the solid and liquid, and collect the first precipitate; S203, the first precipitate is suspended in water and the pH is adjusted to 9.0-11.5, solid-liquid separation is performed to remove insoluble matter, and the first liquid phase is collected; S204, the first liquid phase is contacted with an ion exchange resin to remove ionic impurities and pigments, resulting in a second liquid phase; S205, adjust the pH of the second liquid phase to 2.5-5.0 to cause apigenin to precipitate again, separate the solid and liquid phases, and collect the second precipitate; S206, the second precipitate is dissolved by heating with an organic solvent, then cooled and crystallized to obtain isolated and purified apigenin.

12. The separation and purification method according to claim 11, characterized in that, The large insoluble particles include the bacterial cells.

13. The separation and purification method according to claim 11, characterized in that, In step S204, the volume ratio of the ion exchange resin to the first liquid phase is 1:5 to 1:20, and the contact time is 10-60 minutes.

14. The separation and purification method according to claim 11, characterized in that, In step S206, the organic solvent is selected from at least one of DMSO, ethanol, methanol, and acetone; The heating and melting temperature is 40℃-80℃, and the cooling and crystallization temperature is 0℃-15℃.

15. Apigenin prepared by the production method according to any one of claims 5 to 10 or the separation and purification method according to any one of claims 11 to 14.

16. The use of the AcFNS-I mutant according to claim 1 in the preparation of apigenin.

Citation Information

Patent Citations

  • Flavone synthase and application thereof

    CN110616204A